WATCH LIVE
timothy sykes logo
P3 Health Partners Soars After Dramatic Q1 Turnaround Thumbnail
G Google News

P3 Health Partners Soars After Dramatic Q1 Turnaround

JACK KELLOGG•UPDATED MAY. 16, 2026, 10:06 AM ET
Reviewed by Tim Sykesand Fact-checked by Ellis Hobbs

P3 Health Partners Inc. stocks have been trading up by 126.05 percent amid heightened optimism over its value-based care strategy.

What Traders Need To Know

  • Shares exploded 182% on heavy volume after a swing to Q1 profitability and strong year-over-year revenue growth, signaling a major sentiment shift in P3 Health Partners Inc.
  • Q1 EPS jumped to $0.32 from a loss of $6.28, on revenue rising to $386M and adjusted EBITDA around $26M, prompting higher full-year 2026 EBITDA guidance to a $40M midpoint.
  • Management now targets 2026 revenue of $1.5B–$1.65B and adjusted EBITDA of $20M–$60M, pointing to strong growth with early-stage but positive profitability.
  • A debt-for-equity exchange with Chicago Pacific Founders aims to strengthen the balance sheet and support Nasdaq equity-compliance, reducing delisting overhang for traders.
  • Lake Street lifted its price target from $4 to $14 and reaffirmed a Buy rating, reflecting confidence that restructuring and balance sheet repair can drive multiple expansion.

Candlestick Chart

Weekly Update May 11 – May 15, 2026: On Saturday, May 16, 2026 P3 Health Partners Inc. stock [NASDAQ: PIII] is trending up by 126.05%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

P3 Health Partners occupies a niche value position among Medicare risk-bearing primary care platforms, with ~$1.46B TTM revenue growing >40% over three years but still structurally unprofitable (EBIT margin -18%, pretax margin -30%, ROA about -14% and negative equity). Q1 2026 showed a clear inflection: $386M revenue, $8.2M operating income, and positive GAAP EPS, but operating cash flow was deeply negative and free cash flow was about -$27M, with a thin liquidity profile (current ratio 0.2, quick ratio 0.1).

Technically, PIII has transitioned from a low‑liquidity base around $3.50–4.00 into a high‑momentum breakout, with the stock spiking intraday to $11.92 and closing the week near $9.11 on extreme volume. The dominant trend is now firmly bullish, driven by a short‑squeeze/earnings‑gap dynamic. For traders, $8.50–8.75 is the key actionable level: above this zone, pullbacks are buyable for a momentum continuation; a decisive close below $8.50 likely triggers a fast mean‑reversion toward $6.

Fundamentally, PIII’s Q1 beat, swing to profitability, and raised FY26 adjusted EBITDA guidance ($20–60M, midpoint $40M) mark a credible turnaround versus Healthcare Providers peers that generally already operate solidly profitable MA books. The debt‑to‑equity exchange and Nasdaq compliance progress reduce existential risk and justify some multiple re‑rating, but leverage and negative FCF keep it riskier than sector benchmarks. Base case: high‑volatility re‑rating toward $12–14 over 6–12 months, with support at $8.50 and resistance near $14.

More Breaking News

Quick Financial Overview

P3 Health Partners Inc. just printed the kind of quarter that forces traders to reprice a story fast. The company moved from a large prior-year loss to positive net income in Q1 2026, with EPS at $0.32 versus a $6.28 loss a year ago and net income of about $1.2M. Revenue ticked up to roughly $386M, and adjusted EBITDA near $26M shows that operating leverage is finally coming through after two years of restructuring.

Guidance backs up that inflection. For full-year 2026, P3 Health Partners Inc. is calling for $1.5B–$1.65B in revenue and $20M–$60M in adjusted EBITDA, with management already raising EBITDA guidance to a $40M midpoint. That is a clear move from survival mode toward controlled, profitable growth, even as at-risk membership is deliberately trimmed by 10% to improve unit economics. Key ratios still show scars: negative profit margins, negative book value per share, weak liquidity with a current ratio around 0.2, and heavy debt.

The chart shows how violently the tape reacted. On the weekly data, price sat in the mid-$3s before earnings, then spiked to an $11.92 high and closed the week at $9.11, more than doubling in days. Intraday, one 5‑minute bar captured a move from roughly $5.21 to $14.35 before settling near $11.29, confirming extreme momentum and likely short-covering. With revenue around $1.46B and an enterprise value near $168.86M, the price-to-sales near 0.02 remains depressed, but traders must weigh that apparent value against negative cash flow and a still-fragile balance sheet.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”